188 related articles for article (PubMed ID: 21712506)
41. Anti-factor Xa (anti-Xa) assay.
Newall F
Methods Mol Biol; 2013; 992():265-72. PubMed ID: 23546719
[TBL] [Abstract][Full Text] [Related]
42. Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring.
Frugé KS; Lee YR
Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S90-7. PubMed ID: 26272899
[TBL] [Abstract][Full Text] [Related]
43. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
Levine MN; Hirsh J; Gent M; Turpie AG; Cruickshank M; Weitz J; Anderson D; Johnson M
Arch Intern Med; 1994 Jan; 154(1):49-56. PubMed ID: 8267489
[TBL] [Abstract][Full Text] [Related]
44. Performance of Anti-Factor Xa Versus Activated Partial Thromboplastin Time for Heparin Monitoring Using Multiple Nomograms.
Whitman-Purves E; Coons JC; Miller T; DiNella JV; Althouse A; Schmidhofer M; Smith RE
Clin Appl Thromb Hemost; 2018 Mar; 24(2):310-316. PubMed ID: 29212374
[TBL] [Abstract][Full Text] [Related]
45. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Garcia DA; Baglin TP; Weitz JI; Samama MM
Chest; 2012 Feb; 141(2 Suppl):e24S-e43S. PubMed ID: 22315264
[TBL] [Abstract][Full Text] [Related]
46. Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
Marlar RA; Clement B; Gausman J
Semin Thromb Hemost; 2017 Apr; 43(3):253-260. PubMed ID: 27272964
[TBL] [Abstract][Full Text] [Related]
47. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.
Adatya S; Uriel N; Yarmohammadi H; Holley CT; Feng A; Roy SS; Reding MT; John R; Eckman P; Zantek ND
JACC Heart Fail; 2015 Apr; 3(4):314-22. PubMed ID: 25770404
[TBL] [Abstract][Full Text] [Related]
48. Establishing the heparin therapeutic range using aPTT and anti-Xa measurements for monitoring unfractionated heparin therapy.
Byun JH; Jang IS; Kim JW; Koh EH
Blood Res; 2016 Sep; 51(3):171-174. PubMed ID: 27722127
[TBL] [Abstract][Full Text] [Related]
49. Retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa activity nomograms for therapeutic unfractionated heparin monitoring in pediatrics.
Trucco M; Lehmann CU; Mollenkopf N; Streiff MB; Takemoto CM
J Thromb Haemost; 2015 May; 13(5):788-94. PubMed ID: 25740425
[TBL] [Abstract][Full Text] [Related]
50. Therapeutic monitoring of unfractionated heparin - trials and tribulations.
Baluwala I; Favaloro EJ; Pasalic L
Expert Rev Hematol; 2017 Jul; 10(7):595-605. PubMed ID: 28632418
[TBL] [Abstract][Full Text] [Related]
51. Comparison of anti-Xa and activated partial thromboplastin time monitoring for heparin dosing in patients with cirrhosis.
Fuentes A; Gordon-Burroughs S; Hall JB; Putney DR; Monsour HP
Ther Drug Monit; 2015 Feb; 37(1):40-4. PubMed ID: 24901494
[TBL] [Abstract][Full Text] [Related]
52. Monitoring of unfractionated heparin in critically ill patients.
Aarab R; van Es J; de Pont AC; Vroom MB; Middeldorp S
Neth J Med; 2013 Nov; 71(9):466-71. PubMed ID: 24218420
[TBL] [Abstract][Full Text] [Related]
53. Establishing a therapeutic range for heparin therapy.
Brill-Edwards P; Ginsberg JS; Johnston M; Hirsh J
Ann Intern Med; 1993 Jul; 119(2):104-9. PubMed ID: 8512158
[TBL] [Abstract][Full Text] [Related]
54. A comparison of red blood cell transfusion utilization between anti-activated factor X and activated partial thromboplastin monitoring in patients receiving unfractionated heparin.
Belk KW; Laposata M; Craver C
J Thromb Haemost; 2016 Nov; 14(11):2148-2157. PubMed ID: 27543785
[TBL] [Abstract][Full Text] [Related]
55. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy.
Olson JD; Arkin CF; Brandt JT; Cunningham MT; Giles A; Koepke JA; Witte DL
Arch Pathol Lab Med; 1998 Sep; 122(9):782-98. PubMed ID: 9740136
[TBL] [Abstract][Full Text] [Related]
56. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions.
Faust AC; Kanyer D; Wittkowsky AK
Am J Health Syst Pharm; 2016 Dec; 73(24):2037-2041. PubMed ID: 27919873
[TBL] [Abstract][Full Text] [Related]
57. Accuracy of aPTT monitoring in critically ill patients treated with unfractionated heparin.
van Roessel S; Middeldorp S; Cheung YW; Zwinderman AH; de Pont AC
Neth J Med; 2014 Jul; 72(6):305-10. PubMed ID: 25319855
[TBL] [Abstract][Full Text] [Related]
58. Comment: discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
Muhsin SA; Khianey R; Erkan D
Ann Pharmacother; 2013 Sep; 47(9):1239-40. PubMed ID: 24259747
[No Abstract] [Full Text] [Related]
59. Should we abandon the APTT for monitoring unfractionated heparin?
Arachchillage DRJ; Kamani F; Deplano S; Banya W; Laffan M
Thromb Res; 2017 Sep; 157():157-161. PubMed ID: 28759760
[TBL] [Abstract][Full Text] [Related]
60. Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin.
Wahking RA; Hargreaves RH; Lockwood SM; Haskell SK; Davis KW
Ann Pharmacother; 2019 Aug; 53(8):801-805. PubMed ID: 30813751
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]